Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic response

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Tseng, Chih Wei ^a,b,c,d   Chen, Chi Yi ^e   Chang, Ting Tsung ^f,g   Tzeng, Shinn Jia ^h   Hsieh, Yu Hsi ^a,d   Hung, Tsung Hsing ^a,d   Lee, Ching Chih ^a   Wu, Shu Fen ⁱ   Tseng, Kuo Chih ^a,d  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

^e CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^h NATIONAL CHIAYI UNIVERSITY   (Taiwan)

ⁱ NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG RESPONSE; FATTY LIVER; FEMALE; GENOTYPING TECHNIQUE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTRANSAMINASEMIA; INCIDENCE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; SOCIAL ASPECT; VIRAL CLEARANCE; VIRUS IDENTIFICATION; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DRUG EFFECTS; ENZYMOLOGY; FOLLOW UP; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDY; VIROLOGY; VIRUS LOAD;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; PROGNOSIS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD;

EID: 84903291839     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100207     Document Type: Article

References (37)

1. Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345: 41-52. (Pubitemid 32634271)
2. Omata M, Kanda T, Yu M-L, et al. (2012) APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 6: 409-435.
3. European Association of the Study of the Live. (2012) 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int (Suppl 1): 2-8.
4. Ghany MG, Nelson DR, Strader DB, Thomas DL, American Association for Study of Liver Diseases, et al. (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54: 1433-1444.
5. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
6. Yu ML, Chuang WL (2009) Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 24: 336-345.
7. Chuang WL, Yu ML, Dai CY, Chang WY (2006) Treatment of chronic hepatitis C in southern Taiwan. Intervirology 49: 99-106.
8. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, et al. (2005) Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43: 425-433. (Pubitemid 41111423)
9. Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, et al. (2002) Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy? J Gastroenterol Hepatol 17: 1307-1311. (Pubitemid 35356968)
10. Kim YJ, Jang BK, Kim ES, Park KS, Cho KB, et al. (2012) Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients. Korean J Hepatol 18: 41-47.
11. Kim TY. (2012) The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection. Korean J Hepatol 18: 29-31.
12. Su WP, Peng CY, Lai HC, Liao KF, Huang WH, et al. (2009) Persistent transaminase elevations in chronic hepatitis C patients with virological response during peginterferon and ribavirin therapy. Hepatogastroenterology 56: 798-801.
13. Basso M, Giannini EG, Torre F, Blanchi S, Savarino V, et al. (2009) Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse. Hepatology 49: 1442-1448.
14. Nagashima M, Kudo M, Chung H, Ishikawa E, Inoue T, et al. (2008) Elevated serum ALT levels during PEG-IFN monotherapy may be caused by hepatic iron overload. Intervirology (Suppl 1): 76-85.
15. Thurairajah PH, Thorburn D, Hubscher S, White A, Lai WK, et al. (2007) Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C. Aliment Pharmacol Ther 25: 1293-1300. (Pubitemid 46763458)
16. Ribeiro RM, Layden-Almer J, Powers KA, Layden TJ, Perelson AS (2003) Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 38: 509-517. (Pubitemid 36919873)
17. Aoki YH, Ohkoshi S, Yamagiwa S, Yano M, Takahashi H, et al. (2011) Characterization of elevated alanine aminotransferase levels during pegylated-interferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Hepatol Res 41: 118-125.
18. Ratge D, Scheiblhuber B, Nitsche M, Knabbe C (2000) High-speed detection of blood-borne hepatitis C virus RNA by single-tube real-time fluorescence reverse transcription-PCR with the LightCycler. Clin Chem 46: 1987-1989.
19. Bullock GC, Bruns DE, Haverstick DM (2002) Hepatitis C genotype determination by melting curve analysis with a single set of fluorescence resonance energy transfer probes. Clin Chem 48: 2147-2154. (Pubitemid 35397556)
20. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, et al. (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343: 1666-1672.
21. Chen CH, Huang JF, Huang CF, Yeh ML, Yang JF, et al. (2013) Interferonassociated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy. Hepatol Int 7: 162-170.
22. Foser S, Schacher A, Weyer KA, Brugger D, Dietel E, et al. (2003) Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif 30: 78-87. (Pubitemid 36815235)
23. Grace M, Youngster S, Gitlin G, Sydor W, Xie L, et al. (2001) Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res 21: 1103-1115. (Pubitemid 34121056)
24. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA (2012) Pharmacology and therapeutic potential of interferons. Pharmacol Ther 135: 44-53.
25. Zeuzem S, Welsch C, Herrmann E (2003) Pharmacokinetics of peginterferons. Semin Liver Dis 23 Suppl 1: 23-28. (Pubitemid 37052441)
26. Foster GR (2010) Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs 70: 147-165.
27. Singal AK (2010) Type of pegylated interferon matters: another milestone in the treatment of hepatitis C virus infection. Hepat Mon 10: 165-167.
28. Yang Z, Zhuang L, Yang L, Chen X (2013) Efficacy and tolerability of peginterferon alpha-2a and peginterferon alpha-2b, both plus ribavirin, for chronic hepatitis C: A meta-analysis of randomized controlled trials. Gastroenterol Res Pract 2013: 739029.
29. Romero-Gómez M, Planas R, Ampuero J, Solà R, García-Samaniego J, et al. (2013) Meta-analysis: pegylated interferon alpha-2a achieves higher early virological responses than alpha-2b in chronic hepatitis C. Aliment Pharmacol Ther 37: 1065-1073.
30. Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, et al. (2013) Pegylated interferon-alpha2a and ribavirin versus pegylated interferon-alpha2b and ribavirin in chronic hepatitis C: A meta-analysis. Drugs 73: 263-277.
31. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, et al. (2010) Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 51: 1176-1184.
32. Kraus I, Vitezic D (2001) Acute hepatitis induced by alpha-interferon in a patient with chronic hepatitis C. Can J Gastroenterol 15: 333-335. (Pubitemid 32600128)
33. Cervoni JP, Degos F, Marcellin P, Erlinger S (1997) Acute hepatitis induced by alpha-interferon, associated with viral clearance, in chronic hepatitis C. J Hepatol 27: 1113-1116. (Pubitemid 27523972)
34. Silva MO, Reddy KR, Jeffers LJ, Hill M, Schiff ER (1991) Interferon-induced chronic active hepatitis? Gastroenterology 101: 840-842.
35. Nakamura M, Kanda T, Miyamura T, Wu S, Nakamoto S, et al. (2013) Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment. Int J Med Sci 10: 1015-1021.
36. Webster R, Didier E, Harris P, Siegel N, Stadler J, et al. (2007) PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 35: 9-16. (Pubitemid 46036470)
37. Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, et al. (2005) Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 12: 283-291.